Glial-Enriched Progenitor Cell Therapy for White Matter Stroke Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There are no effective therapies available for white matter stroke, which affects up to 25% of strokes occurring annually and contributes to cognitive decline and dementia, due to its unique pattern of cellular injury involving oligodendrocytes, OPCs, and astrocytes, unlike large artery stroke.
Innovation Solution
Administering therapeutically effective amounts of human induced pluripotent glial-enriched progenitor cells into or adjacent to the infarct core in the brain during the subacute period after ischemic injury, using a depot delivery system such as a hydrogel to support cell survival and integration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional stroke therapies are used for white matter stroke, then treatment is provided, but the therapies are ineffective due to the unique pattern of cellular injury in white matter stroke
Solution Approach 1:
The patent applies local quality by using glial-enriched progenitor cells specifically tailored for white matter stroke pathology. These cells are differentiated to express glial markers (GFAP, S100β) and are designed to target the specific cellular injury pattern in white matter (oligodendrocytes, OPCs, astrocytes) rather than using generic stroke therapies. The cells migrate to and integrate into the injured white matter regions, providing localized treatment adapted to the specific tissue damage pattern.
Solution Approach 2:
The patent employs parameter changes by altering the cellular composition and differentiation state of the therapeutic agent. Instead of using undifferentiated stem cells or neuron-enriched progenitors, the invention uses glial-enriched progenitor cells with specific glial marker expression. This parameter change in cell type specification makes the therapy effective for white matter stroke, which has a distinct cellular injury profile compared to large artery stroke.
2Reliability
If stem cell therapy is administered to promote neural repair, then cell survival and integration are needed, but cell death and poor integration occur without proper support
Solution Approach 1:
The patent uses a depot delivery system as an intermediary between the administered stem cells and the target tissue. This depot acts as a temporary scaffold that maintains cell viability, controls cell release, and facilitates integration into the host tissue. The depot provides a protected environment that shields the vulnerable stem cells from the hostile post-stroke environment, enabling successful engraftment and therapeutic effect.
Solution Approach 2:
The depot delivery system performs preliminary action by pre-preparing a supportive matrix before cell administration. The depot is implanted or injected into the injured area beforehand, creating a favorable microenvironment that promotes cell survival and integration. This preliminary preparation ensures that when stem cells are introduced, they immediately encounter a supportive rather than hostile environment, significantly improving engraftment success.
Data Source
AI summary
In various embodiments methods and compositions for improving a recovery of a subject after a cerebral ischemic injury, such as white matter stroke are provided. In certain embodiments, the methods involve administering human induced pluripotent glial enriched progenitor cells into the brain of the subject.